Drug intelligence / Profile preview

CS-11

Development stage: Preclinical
Lead developer: CelSiege Biosciences
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CS-11 is a next-generation therapeutic vaccine developed by CelSiege Biosciences for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors. It utilizes a B cell-mediated immunotherapy approach to break immune tolerance and induce the production of endogenous polyclonal antibodies against both Epidermal Growth Factor (EGF) and Transforming Growth Factor alpha (TGFα). By dual-targeting these growth factors, CS-11 aims to inhibit the signaling pathways that drive tumor proliferation and survival. The drug is currently in preclinical development and is administered via intramuscular injection.

Targets

TGFA (Transforming growth factor alpha)

Beyond the preview

Go deeper on CS-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS-11.

Explore the full profile